Viatris Inc has provided a proliferation of updates regarding their financial status, corporate structure, project advancements, and pending litigation. Key points to note include their established plan to present Q1 2025 earnings on May 8, 2025, as well as the release of their Q4 2024 and full-year 2024 results, establishing their financial standing. The company, unusually, is also under scrutiny from investment law firms and investors who are investigating potential fraud. Interestingly, the billionaire David Einhorn is reportedly keen on Viatris stocks. Other developments include the company’s scheduled appearance at the Barclays 27th Annual Global Healthcare Conference and the completion of their planned divestitures. Furthermore, their drug, Cenerimod, has passed a Phase 2b CARE study with its results published in Lancet Rheumatology. Finally, Viatris confirmed the FDA’s acceptance of the New Drug Application for GA Depot - a treatment for multiple sclerosis, filed in partnership with Mapi Pharma. Additionally, Viatris, in partnership with Kindev, launched their FDA-approved generic Asthma and Chronic Obstructive Pulmonary Disease medication, Breyna™. Scott A. Smith was appointed as the company’s CEO effective April 1, 2023.
Viatris VTRS News Analytics from Mon, 27 Feb 2023 08:00:00 GMT to Sat, 29 Mar 2025 01:33:31 GMT -
Rating -1
- Innovation 0
- Information 7
- Rumor -3
